MLTX — MoonLake Immunotherapeutics Share News
0.000.00%
Last trade - 00:00MoonLake Immunotherapeutics jumps on rival Acelyrin's setback
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering Of Upto $1 Billion - SEC Filing
Brief: Moonlake Completes Patient Randomization For Phase 2 Trial In Active Psoriatic Arthritis
MoonLake Immunotherapeutics explores sale-sources
MoonLake Immunotherapeutics explores sale-sources
Brief: Moonlake Immunotherapeutics Says On June 27, Entered Into Underwriting Agreement To Issue, Sell 8,000,000 Class A Ordinary Shares
Brief: MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
MoonLake Immunotherapeutics jumps as skin condition drug trial meets goal
MoonLake Immunotherapeutics gains on smaller-than-expected Q1 loss
Brief: MoonLake Immunotherapeutics Says Expected Cash Runway Extended To End Of 2024
MoonLake Immunotherapeutics rises on collaboration with SHL Medical
Brief: MoonLake Immunotherapeutics Files For Mixed Shelf Of Up To $500 Million – SEC Filing
MoonLake falls on wider loss than previous quarter
Brief: Moonlake Immunotherapeutics Reports Fourth Quarter And Year-End 2022 Financial Results And Provides A Business Update
Brief: Moonlake Immunotherapeutics Does Not Hold Cash Deposits Or Securities With SVB
Brief: MoonLake Immunotherapeutics Completes Patient Enrollment, Randomization Ahead Of Phase 2 Trial Of Nanobody Sonelokimab
Brief: MoonLake Immunotherapeutics Screens First Patient In Phase 2 Study Of The Nanobody® Sonelokimab In Active Psoriatic Arthritis
Brief: Moonlake Immunotherapeutics Reports Q3 Financial Results, Provides Recent Business Update
U.S. STOCKS ON THE MOVE-UnitedHealth, Lifestyle, Exxon